Edition:
United States

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

20.20USD
22 May 2017
Change (% chg)

$0.25 (+1.25%)
Prev Close
$19.95
Open
$20.05
Day's High
$20.30
Day's Low
$19.75
Volume
69,538
Avg. Vol
170,034
52-wk High
$39.95
52-wk Low
$16.75

LCI.N

Chart for LCI.N

About

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June... (more)

Overall

Beta: 2.73
Market Cap(Mil.): $742.75
Shares Outstanding(Mil.): 37.23
Dividend: --
Yield (%): --

Financials

  LCI.N Industry Sector
P/E (TTM): -- 14.32 17.37
EPS (TTM): -0.09 -- --
ROI: -0.18 -7.73 -5.89
ROE: -0.50 -7.36 -5.30

BRIEF-Lannett announces FDA approval for levocetirizine dihydrochloride oral solution, 2.5 mg/5 ml

* Lannett announces approval for levocetirizine dihydrochloride oral solution, 2.5 mg/5 ml (0.5 mg/ml)

May 16 2017

BRIEF-Lannett Company Inc files for potential mixed shelf size not disclosed

* Lannett Company Inc files for potential mixed shelf; size not disclosed - sec filing Source text (http://bit.ly/2raUzkw) Further company coverage:

May 12 2017

BRIEF-Lannett voluntarily pays down remaining $25 mln principal balance of revolving credit facility

* Lannett voluntarily pays down remaining $25 million principal balance of revolving credit facility

May 09 2017

BRIEF-Lannett voluntarily pays down additional $25 mln of revolving credit facility

* Lannett voluntarily pays down additional $25 million of revolving credit facility

Mar 30 2017

BRIEF-Lannett Co says FDA agreed to delay submission deadline for Methylphenidate ER tablets

* Lannett provides further update on methylphenidate er tablets

Feb 22 2017

BRIEF-Lannett announces successful completion of ERP system extraction

* Lannett announces successful completion of ERP system extraction Source text for Eikon: Further company coverage:

Feb 07 2017

BRIEF-Lannett's subsidiary to launch $50 mln expansion - SEC filing

* Lannett Company Inc - Cody Laboratories, a wholly owned subsidiary of company, would be launching a $50 million expansion to its facilities - SEC filing Source text for Eikon: Further company coverage:

Jan 31 2017

BRIEF-Lannett announces approval for Metaxalone Tablets

* Lannett announces approval for Metaxalone Tablets USP, 800 mg

Nov 28 2016

More From Around the Web

Competitors

  Price Chg
AbbVie Inc (ABBV.N) $65.44 -0.14
Pfizer Limited (PFIZ.NS) Rs1,708.30 -18.20
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs2,590.05 -18.65

Earnings vs. Estimates